Are You Holding the Right Stock?
Gene editing stocks have been seeing a lot of volatility lately as the first $2 million CRISPR drug hits the market. CASGEVY is the first approved therapy in the U.S. that uses CRISPR and it’s no quick fix for sickle cell disease (SCD), a group of inherited blood disorders affecting approximately 100,000 people in the United States. Stem cells are collected from patients and sent to a lab where the actual CRISPR editing is done, and the entire process takes months, even up to a year. Today we'll look at CRISPR Therapeutics stock as well as their peers in the gene editing space: Intellia…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.